Impact of SARS-CoV-2 Load on COVID-19 Complications
Author Information
Author(s): Tomas O. Jensen, Katrina Harper, Shaili Gupta, Sean T. Liu, Nila J. Dharan, Jason V. Baker, Sarah L. Pett, Kathryn Shaw-Saliba, Aliasgar Esmail, Minh Q. Ho, Eyad Almasri, Robin L. Dewar, Jens Lundgren, David M. Vock
Primary Institution: Rigshospitalet, University of Copenhagen
Hypothesis
How does the baseline SARS-CoV-2 load in plasma and upper airways affect the incidence of acute extrapulmonary complications in COVID-19 patients?
Conclusion
Higher levels of SARS-CoV-2 in the body are linked to more complications and higher mortality in COVID-19 patients.
Supporting Evidence
- 20.5% of participants experienced at least one extrapulmonary complication.
- Higher plasma nucleocapsid antigen levels were associated with increased risk of complications.
- Extrapulmonary complications were linked to a higher 90-day mortality rate.
- Patients with high viral loads had a significantly increased risk of complications.
- Trial treatment allocation did not affect the risk of extrapulmonary complications.
Takeaway
This study found that patients with higher amounts of the virus in their blood and airways are more likely to have serious health problems and die from COVID-19.
Methodology
This was a prospective cohort study involving patients hospitalized for COVID-19 across 114 international sites, analyzing the relationship between viral load and extrapulmonary complications.
Potential Biases
Potential confounding factors related to treatment allocation and vaccination status.
Limitations
The study population was predominantly unvaccinated and enrolled before the emergence of the Omicron variant.
Participant Demographics
Median age was 57 years, 57.7% were male, and 82.9% had at least one comorbid condition.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 7.3–12.7
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website